explore -WSS

explore

author：comprehensive 2025-09-06 02:04:59 - browse：9641

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Senate HELP committee spars over health care workforce policies

explore

WSS

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

ProMED, early warning system on disease outbreaks, in peril

Senators: Long

FDA panel to weigh approval of NurOwn, controversial ALS drug

TytoCare raises $49 million to build out AI

Why are Kaiser Permanente staff considering a strike?

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Walensky prepares to leave CDC — and Congress — behind

'Ancient DNA,' 23andMe reveal African American ancestries

Wildfire smoke exposes gaps in outdoor worker protections

Humana, CVS hope to turn members into patients at clinics

After affirmative action ruling, medical educators look to 'holistic review'

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Trump demands the U.S. pay no more for drugs than other countries … again

Verily hires former Apple Health leader as chief scientific officer

Novavax promises a turnaround & Lilly roils the obesity market

CDC's new outbreak response network to include Northeastern

entertainment

Verily hires former Apple Health leader as chief scientific officer

How Vertex's cystic fibrosis drug is changing patients' lives

Microsoft strikes partnership with Duke Health to advance health AI

Gilgo Beach: Police identify another victim in serial killing investigation

'Ancient DNA,' 23andMe reveal African American ancestries

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

leisure time

hotspot

explore

knowledge